Enzo Biochem (ENZ)

[DrShocker]

Up from 2.95. But for how long?

[Transparency]

Not sure why this is down over 12% today, but I got in @ $2.54. Hope to take advantage of a bounce tomorrow?

[Spicknspan]

This stock has gone nowhere over the past ten years. Ugh

[alphaInvestor2]

Anyone else think we fly soon?

[surf1944]

9:18AM Enzo Biochem announces upcoming litigation schedule; co awarded $61 mln in damages (ENZ) 2.74 : Co issued an update on its ongoing litigation surrounding the protection of its intellectual property and contractual rights. Two of the cases, in which Enzo is the Plaintiff, are scheduled for jury trials. Both cases will be tried in the United States District Court for the Southern District of New York in New York City.

In the case of Enzo Biochem v. PerkinElmer, 03-cv-03817, the Court has scheduled a jury trial to begin March 18, 2014
In the case of Enzo Life Sciences v. Affymetrix, 04-cv-01555, a jury trial has been scheduled for May 5, 2014
Enzo sued PerkinElmer for, among other things, breach of contract and patent infringement, claiming that the company was subject to an agreement to distribute Enzo's patented nucleotide labeling technologies for research purposes, but then distributed the technologies for clinical use without Enzo's authorization. Enzo sued Affymetrix for, among other things, breaching their distribution agreement by misappropriating Enzo technologies and manufacturing and selling Enzo products in violation of the terms of the agreement.z

In a recent ruling, another Federal Court, the United States District Court for the District of Connecticut, awarded Enzo over $61.0 million in damages and interest in connection with Enzo's patent infringement lawsuit against Applera Corp., now Life Technologies, Inc.

[surf1944]

10:40AM Enzo Biochem confirms Federal Court awarded it over $61 million in patent infringement damages (ENZ) 3.35 +0.45 :

Co reported that a Federal Court Judge in New Haven, CT, in connection with the favorable November 2012 jury finding of direct infringement damages of Enzo patents by Applera, now Life Technologies (LIFE), has awarded the Company prejudgment interest of $12,428,729, bringing the total award to in excess of $61 million.
Additional post-interest on the full amount was also awarded starting November 7, 2012 until the total judgment is satisfied, which, it is estimated, could add several additional millions.

[southpawplayer23]

And covered again....

[southpawplayer23]

Shorting again. News already hit all wires and people will sell for profit

[janderson2000]

After hours ask at $3.15 right now! Big gap up tomorrow???

[southpawplayer23]

Bought to cover with profit ill cya guys later... Never coming back

[janderson2000]

Too much profit taking...

[janderson2000]

Good support at 2.55-2.60, leading into tomorrow's big jump on the open. Crossing my fingers!

[janderson2000]

I'll sell tomorrow after big open on news. This volume will attract many eyes today.

[~ NT ~]

I played the 200 DMA breakout - sold out with the volume for some gains - I may play again - On watch now - it needs to stay above the 200 DMA.

I wish you all good luck. Its a great find

[rayinbrooklyn65]

Enzo Biochem Decision Opens Doors...

The decision by the Federal Court to award $48.6 mln in direct infringement damages as a result of Applera having infringed Enzo's patent relating to compounds used in DNA sequencing systems. The judge's ruling opens the way for Enzo's recovery of prejudgment interest on the damages award, which should exceed $25 mln in addition to the judgment.

This will allow the company to expand and move forward with its core business, which should increase the value of the company's stock.

[janderson2000]

Hope you held, cause we're going higher. In @ 2.47.

[~ NT ~]

Great call SM. I made some $$$ on it. Weeeeee.

GL

[lowman]

Like I said: theoretically.

[janderson2000]

19k on the bid. I'm holding.

[southpawplayer23]

It's not as easy as that. That was so basic. Valuation on the settlement needs to include court fees, lawyers fees etc.. Yes they got a lot of money but what else has been positive for this company??? Without the settlement the company is just too unpredictable.

[JUST 10-11-12]

lots of monies coming in

[janderson2000]

Today's volume is going to bring quite a few eyes over to ENZ tonight and the rest of the week. It's gonna be a beautiful week!

[janderson2000]

Sounds good to me!

[JUST 10-11-12]

good logic!

[lowman]

o/s is 40M. Judgement is $46M + $25M. That's a total of $1.75 p/share. ENZ opened at $2.23. Theoretically, this could run close to $4.

[lowman]

Definitely a bad move. What was he thinkin! lol

[janderson2000]

Think this is more of a game changer for ENZ, especially if they will continue to see royalties.

[southpawplayer23]

Looking for a pump on news and then dying out a bit... That's all. Good luck to you.

[JUST 10-11-12]

NO GAP! is right

[janderson2000]

Yeah he made a bad move shorting this. Just hit 2.76 before pulling back a little.

[lowman]

Don't be so sure. Gaps created by substantial fundamental developments often go unfilled.

Besides, there ain't no gap in this chart!

[southpawplayer23]

Just shorted some at 2.60 gotta fill that gap

[janderson2000]

That ~$75 mil will look good on their next quarterly statement. We'll be above $3 in no time!

[TheFinalCD]

$2.63 weeeeeeeeee

[janderson2000]

Whoop new HoD lets hit $3+ today!

[janderson2000]

Oh yeah people are back from lunch moving up big time!!!

[Danna]

Nice NEWS $$$$$$ $ENZ

[Komando Robot]

2.52

[janderson2000]

L.I.F.E ticker starting to take a hit from the verdict. ENZ was $12 at one point, but most recently $3. I think we can see much higher than $3, especially if ongoing royalties have to be paid.

[JUST 10-11-12]

going to the highs!

[TheFinalCD]

$2.50

[TheFinalCD]

Enzo Biochem Inc. (NYSE:ENZ) reported today that a Federal Court Judge in New Haven, CT, has upheld the jury verdict issued in November 2012 which awarded Enzo $48.6 million in direct infringement damages as a result of Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE) having infringed Enzo’s patent covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The judge’s ruling opens the way for Enzo’s recovery of prejudgment interest on the damages award, which should exceed $25 million in addition to the judgment

[HDOGTX]

Shazam, wam bam, thank you mamme

[TheFinalCD]

MEGA NEW$$$$$$$$

[janderson2000]

People just getting back from lunch. Once they see the news, prepare for an afternoon rush!

[janderson2000]

HUGE NEWS!!!

Court Upholds $48.6 Million Jury Award to Enzo Biochem
47 minutes ago - DJNF

NEW YORK--(BUSINESS WIRE)--August 05, 2013--
Enzo Biochem Inc. (NYSE:ENZ) reported today that a Federal Court Judge in New Haven, CT, has upheld the jury verdict issued in November 2012 which awarded Enzo $48.6 million in direct infringement damages as a result of Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE) having infringed Enzo's patent covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The judge's ruling opens the way for Enzo's recovery of prejudgment interest on the damages award, which should exceed $25 million in addition to the judgment.
The Enzo action is entitled Enzo Biochem, Inc. et al. vs. Applera Corp. and Tropix Inc. in New Haven, CT Civil Action No. 3:04cv929 (JBA).
"We are pleased with the Judge's decision which, in addition to the monetary award, we anticipate will have a positive impact on the resolution of pending actions that Enzo brought in the U.S. Southern District Court in New York City, which involve additional defendants, patents and contract issues," said Barry Weiner, Enzo President.
In addition to leaving the jury verdict undisturbed, the Judge also denied Life Technologies' request for a finding that Enzo's infringement claims are barred by laches and/or equitable estoppel, as well as its motion for a new trial and denied Enzo's request for reconsideration seeking additional damages.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2012. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

CONTACT: For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
[e-mail]
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
[e-mail]

SOURCE: Enzo Biochem, Inc.
Copyright Business Wire 2013

Order free Annual Report for Enzo Biochem, Inc.
Visit http://djnweurope.ar.wilink.com/?ticker=US2941001024 or call [phone]
(END) Dow Jones Newswires
August 05, 2013 12:08 ET (16:08 GMT)

[Danna]

News on boards!

[TheFinalCD]

nice timing!

[Danna]

NEWS OF SETTLEMENT!!!!!!!!

http://ih.advfn.com/p.php?pid=nmona&article=58685491

Court Upholds $48.6 Million Jury Award to Enzo Biochem
Print
Alert
Enzo Biochem (NYSE:ENZ)
Intraday Stock Chart

Today : Monday 5 August 2013
Click Here for more Enzo Biochem Charts.

Enzo Biochem Inc. (NYSE:ENZ) reported today that a Federal Court Judge in New Haven, CT, has upheld the jury verdict issued in November 2012 which awarded Enzo $48.6 million in direct infringement damages as a result of Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE) having infringed Enzo’s patent covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The judge’s ruling opens the way for Enzo’s recovery of prejudgment interest on the damages award, which should exceed $25 million in addition to the judgment.

The Enzo action is entitled Enzo Biochem, Inc. et al. vs. Applera Corp. and Tropix Inc. in New Haven, CT Civil Action No. 3:04cv929 (JBA).

“We are pleased with the Judge’s decision which, in addition to the monetary award, we anticipate will have a positive impact on the resolution of pending actions that Enzo brought in the U.S. Southern District Court in New York City, which involve additional defendants, patents and contract issues,” said Barry Weiner, Enzo President.

In addition to leaving the jury verdict undisturbed, the Judge also denied Life Technologies’ request for a finding that Enzo’s infringement claims are barred by laches and/or equitable estoppel, as well as its motion for a new trial and denied Enzo’s request for reconsideration seeking additional damages.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2012. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.


For Enzo Biochem, Inc.

Anreder & Company

Steven Anreder, 212-532-3232

[Danna]

Nice.....$$$$$$$$$$$$$$$$$$$$$$$ coming!